Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid

Acadia Pharma (ACAD) Fades Early Gains

Acadia Pharma (NASDAQ: ACAD) is fading early gains after an FDA panel backed the company's Nuplazid.

Worries about a potential Black Box Warning could be to blame.

Shares are up 9.8% after opening up 20%.

Aegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval Soon

Aegis Capital affirms Acadia Pharma (Nasdaq: ACAD) with a Buy rating and $54 price target following a positive FDA panel review of Acadia's Nuplazid on Tuesday.

Analyst Robert LeBoyer sees post-approval studies for Nuplazid, commenting, Following the results of the Phase III trial in 2013, Acadia met with the FDA and was encouraged to file based only on that trial. Its strong results... More

Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZID

Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $44.00 (from $39.00) after an FDA panel voted positively on three questions regarding efficacy, and safety.

"Given the clear numerical results, and opinions voiced during... More

After-Hours Stock Movers 03/29: (ACAD) (AGIO) Higher; (LNDC) (VRNT) (CTRV) Lower (more...)

Acadia Pharma (NASDAQ: ACAD) 21.8% HIGHER; FDA panel backing for NUPLAZID.

Landec (NASDAQ: LNDC) 12.6% LOWER; reported Q3 EPS of $0.01, $0.02 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $130 million versus the consensus estimate of $136.99 million. GUIDANCE: Landec sees FY2016 EPS of $0.33-$0.37, versus the consensus of $0.39.

Verint Systems (NASDAQ: VRNT) 11.9% LOWER;... More

Acadia Pharma (ACAD) Surges 25% as Trading Resumes

Acadia Pharma (NASDAQ: ACAD) is trading up 25.6% as trading resume following FDA panel backing for NUPLAZID.

Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ET

Acadia Pharma (NASDAQ: ACAD) Resumes Trading at 5:45 PM ET

Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's Disease

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinsons disease outweigh the risks of... More

Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - Bloomberg

Acadia Pharma (NASDAQ: ACAD) wins FDA panel backing for Nuplazid, according to Bloomberg.

Acadia Pharma (ACAD) adequately characterized the safety profile of NUPLAZID - FDA Panel

Acadia Pharma (NASDAQ: ACAD) received another positive FDA panel vote for NUPLAZID (pimavanserin) today. The following is the most recent question in the review:

2. Has Acadia adequately characterized the safety profile of pimavanserin?

Acadia Pharma's (ACAD) NUPLAZID Seen Effective in Parkinson's - FDA Panel

Acadia Pharma (NASDAQ: ACAD) received a positive FDA panel vote for pimavanserin in treating at least one disease. The following question was posed Tuesday:

1. VOTE: Has Acadia provided substantial evidence of effectiveness for NUPLAZID (pimavanserin) for the treatment of psychosis w/ PD?

12 panelists voted 'yes,' while 2 voted 'no.'

Acadia Pharma (ACAD) Said Facing 'Tough' Nuplazid Efficacy Questions from FDA Panel

Acadia Pharma (NASDAQ: ACAD) is said to be facing tough questions on the efficacy of Nuplazid. The following was posted by pharma-watcher Adam Feuerstein to Twitter on Tuesday:

... More

Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that NASDAQ has halted trading of the companys common stock.

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to review NUPLAZID (pimavanserin) for the treatment of patients with... More

Acadia Pharma (ACAD) trading halted with news pending

Acadia Pharma (NASDAQ: ACAD) trading halted with news pending.

Acadia Pharma's (ACAD) Buy Rating Reiterated at H.C. Wainwright Ahead of Nuplazid's Adcom Meeting

H.C. Wainwright reiterated a Buy rating on Acadia Pharmaceuticals (NASDAQ: ACAD) with a price target of $50. Comments follow the release of FDA briefing documents for tomorrow's Nuplazid FDA adcom panel. Analyst Andrew S. Fein said he remains confident that clinical benefits outweigh risks.

"As anticipated, the discussion will center on clinical meaningfulness of the 3-point improvement on SAPS-PD and risk/reward in light of safety signals, including potential... More

Leerink Affirms ACADIA Pharma (ACAD) at 'Outperform'; Pimavanserin Briefing Docs More Crticial than Expected

Leerink affirms ACADIA Pharma (Nasdaq: ACAD) with an Outperform rating and $40 price target after the FDA Psychopharmacologic Drugs Advisory Committee released the pimavanserin briefing documents last Friday.

Analyst... More

Acadia Pharma (ACAD) Shares Active Ahead of NUPLAZID FDA Panel

Acadia Pharma (NASDAQ: ACAD) shares advanced pre-market after the FDA posted briefing documents ahead of its NUPLAZID panel on March 29. The documents are embedded below: